What the Options Market Tells Us About Gilead Sciences
What the Options Market Tells Us About Gilead Sciences
Deep-pocketed investors have adopted a bullish approach towards Gilead Sciences (NASDAQ:GILD), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in GILD usually suggests something big is about to happen.
財力雄厚的投資者對吉利德科學（納斯達克股票代碼：GILD）採取了看漲態度，這是市場參與者不容忽視的。我們對本辛加公開期權記錄的追蹤今天揭示了這一重大舉措。這些投資者的身份仍然未知，但是GILD的如此重大變動通常表明即將發生重大事件。
We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Gilead Sciences. This level of activity is out of the ordinary.
我們今天從觀察中收集了這些信息，當時Benzinga的期權掃描儀重點介紹了吉利德科學的8項非凡期權活動。這種活動水平與衆不同。
The general mood among these heavyweight investors is divided, with 50% leaning bullish and 50% bearish. Among these notable options, 3 are puts, totaling $93,168, and 5 are calls, amounting to $211,849.
這些重量級投資者的總體情緒存在分歧，50％的人傾向於看漲，50％的人看跌。在這些值得注意的期權中，有3個是看跌期權，總額爲93,168美元，5個是看漲期權，總額爲211,849美元。
Expected Price Movements
預期的價格走勢
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $65.0 to $75.0 for Gilead Sciences over the last 3 months.
考慮到這些合約的交易量和未平倉合約，在過去的3個月中，鯨魚似乎一直將吉利德科學的價格定在65.0美元至75.0美元之間。
Insights into Volume & Open Interest
對交易量和未平倉合約的見解
In today's trading context, the average open interest for options of Gilead Sciences stands at 770.43, with a total volume reaching 765.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Gilead Sciences, situated within the strike price corridor from $65.0 to $75.0, throughout the last 30 days.
在當今的交易背景下，吉利德科學期權的平均未平倉合約爲770.43，總成交量達到765.00。隨附的圖表描繪了過去30天吉利德科學高價值交易的看漲期權和看跌期權交易量以及未平倉合約的變化，行使價走勢從65.0美元到75.0美元不等。
Gilead Sciences Option Volume And Open Interest Over Last 30 Days
吉利德科學過去 30 天的期權交易量和未平倉合約
Significant Options Trades Detected:
檢測到的重要期權交易：
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| GILD | CALL | SWEEP | BEARISH | 01/17/25 | $2.88 | $2.76 | $2.76 | $75.00 | $67.6K | 1.8K | 6 |
| GILD | CALL | SWEEP | BEARISH | 11/15/24 | $4.9 | $4.75 | $4.78 | $67.50 | $48.8K | 174 | 31 |
| GILD | CALL | SWEEP | BEARISH | 11/15/24 | $5.05 | $4.75 | $4.79 | $67.50 | $44.3K | 174 | 257 |
| GILD | PUT | TRADE | BULLISH | 11/15/24 | $4.4 | $4.2 | $4.25 | $65.00 | $42.5K | 936 | 50 |
| GILD | CALL | TRADE | BULLISH | 08/16/24 | $3.45 | $3.3 | $3.4 | $67.50 | $25.5K | 83 | 215 |
| 符號 | 看跌/看漲 | 交易類型 | 情緒 | Exp。日期 | 問 | 出價 | 價格 | 行使價 | 總交易價格 | 未平倉合約 | 音量 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 金 | 打電話 | 掃 | 粗魯的 | 01/17/25 | 2.88 美元 | 2.76 美元 | 2.76 美元 | 75.00 美元 | 67.6 萬美元 | 1.8K | 6 |
| 金 | 打電話 | 掃 | 粗魯的 | 11/15/24 | 4.9 美元 | 4.75 美元 | 4.78 美元 | 67.50 美元 | 48.8 萬美元 | 174 | 31 |
| 金 | 打電話 | 掃 | 粗魯的 | 11/15/24 | 5.05 美元 | 4.75 美元 | 4.79 美元 | 67.50 美元 | 44.3 萬美元 | 174 | 257 |
| 金 | 放 | 貿易 | 看漲 | 11/15/24 | 4.4 美元 | 4.2 美元 | 4.25 美元 | 65.00 美元 | 42.5 萬美元 | 936 | 50 |
| 金 | 打電話 | 貿易 | 看漲 | 08/16/24 | 3.45 美元 | 3.3 美元 | 3.4 美元 | 67.50 美元 | 25.5 萬美元 | 83 | 215 |
About Gilead Sciences
關於吉利德科學
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
吉利德科學開發和銷售治療危及生命的傳染病的療法，其產品組合的核心集中在艾滋病毒以及乙型和丙型肝炎上。對Corus Pharma、Myogen、CV Therapeutics、Arresto Biosciences和Calistoga的收購擴大了這一關注範圍，將肺部和心血管疾病以及癌症包括在內。吉利德對Pharmasset的收購帶來了丙型肝炎藥物Sovaldi的版權，該藥物也是複方藥物Harvoni的一部分，而對Kite、Forty Seven和Immunomedics的收購增加了吉利德在腫瘤學領域接受細胞療法和非細胞療法的機會。
After a thorough review of the options trading surrounding Gilead Sciences, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
在對圍繞吉利德科學的期權交易進行了全面審查之後，我們將對該公司進行更詳細的審查。這包括評估其當前的市場狀況和表現。
Gilead Sciences's Current Market Status
吉利德科學的當前市場狀況
- With a trading volume of 2,746,138, the price of GILD is down by -1.33%, reaching $66.04.
- Current RSI values indicate that the stock is may be oversold.
- Next earnings report is scheduled for 7 days from now.
- GILD的交易量爲2746,138美元，價格下跌了-1.33％，至66.04美元。
- 當前的RSI值表明該股票可能被超賣。
- 下一份收益報告定於7天后發佈。
What Analysts Are Saying About Gilead Sciences
分析師對吉利德科學的看法
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $75.0.
在過去的一個月中，1位行業分析師分享了他們對該股的見解，提出平均目標價爲75.0美元。
- Maintaining their stance, an analyst from UBS continues to hold a Neutral rating for Gilead Sciences, targeting a price of $75.
- 瑞銀的一位分析師保持立場，繼續對吉利德科學維持中性評級，目標價格爲75美元。
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
與僅交易股票相比，期權是一種風險更高的資產，但它們具有更高的獲利潛力。嚴肅的期權交易者通過每天自我教育、擴大交易規模、關注多個指標以及密切關注市場來管理這種風險。
譯文內容由第三人軟體翻譯。